AzTrials
AzTrials

Spinal Cord InjuriesNCT05643313

Clinical Investigation on Feasibility and Usability of the ABLE Exoskeleton Device for Individuals With Spinal Cord Injury to Perform Skills for Home and Community Environments

A study testing ABLE Exoskeleton in people with Spinal Cord Injuries, run by ABLE Human Motion S.L. at 2 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Spinal Cord Injuries
What is being tested?
ABLE Exoskeleton
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
2 sitesin 2 countries
Study dates
25 Nov 2022to 28 Aug 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 to 70 years of age
  • Traumatic and non-traumatic SCI
  • Motor incomplete SCI with Neurological Level of Injury (NLI) C5-L5, or, Motor Complete SCI with NLI T1-L5
  • Time since onset of SCI > 6 months
  • Ability to give informed consent

Who cannot join

  • WISCI II without exoskeleton of >13
  • 5 or more risk factors present for fragility as stated by Craven et al (Craven et al., 2009a).
  • History of lower limb fragility fractures in the last 2 years
  • Deterioration > 3 points of the total ISNCSCI motor score within the last 4 weeks
  • Spinal instability
  • Modified Ashworth scale 4 in lower limbs
Show all 16Show fewer
  • Unable to tolerate 30 min standing without clinical symptoms of orthostatic hypotension
  • Unable to perform a sit-to-stand transfer or stand in the device with assistance
  • Psychological or cognitive issues that do not allow the participant to follow the study procedures
  • Known pregnancy or breastfeeding
  • Any neurological condition other than SCI
  • Medically unstable - Unstable cardiovascular system, hemodynamic instability, untreated hypertension (Systolic blood pressure > 140, Diastolic blood pressure > 90 mmHg), unresolved DVT, uncontrolled autonomic dysreflexia.
  • Severe comorbidities - Any condition that a physician considers to not be appropriate to complete participation in the study.
  • Ongoing skin issues - Grade I or higher on EPUAP on areas that will be in contact with exoskeleton (European Pressure Ulcer Advisory Panel, 2019)
  • Height, width, weight or other anatomical constraints (such as leg length differences) incompatible with the device
  • Range of motion (ROM) restrictions in lower extremities, that are incompatible with the device

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

Germany1 site

  • Spinal Cord Injury Center | Heidelberg University Hospital

    Heidelberg, 69118

Other trials in Germany

Spain1 site

  • Institut Guttmann

    Badalona, Barcelona, 08916

Other trials in Spain

About this study

The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians. Exoskeletal technology has the potential to help people with impaired leg function to regain ambulation and thus improve their independence. This technology is not completely new, but due to their high access price (~120k€/unit), high size and weight (~25 kg), and need for trained physiotherapist supervision, commercially available exoskeletons are only found in large hospitals and only in very few cases get into patients' homes.

The company ABLE Human Motion S.L. (Barcelona, Spain) has developed a novel exoskeleton to overcome these disadvantages, which is more compact, lighter and easier to use.

The primary objective of this study is to determine the feasibility and usability of the ABLE Exoskeleton for persons with SCI to perform skills in home and community environments.

Read the detailed description

The primary objective of this study is to determine the feasibility and usability of the ABLE Exoskeleton for persons with SCI to perform skills for home and community environments during a training programme of up to 8 weeks. Results will be used to assess the potential of the device to be used in a home and community setting by persons with SCI, while providing meaningful insights to develop future features to improve its performance in those environments.

The secondary objectives are as follows:

  • Assess the impact of ABLE Exoskeleton training on gait and function.
  • Assess the effect of the ABLE Exoskeleton on the patients' perceived rate of exertion.
  • Assess the impact of the ABLE Exoskeleton on the quality of life and general health of the participants.
  • Assess the level of user satisfaction from participants and therapists of the ABLE Exoskeleton.
  • Assess the psychosocial impact of the ABLE Exoskeleton for participants.

The primary hypothesis of this study is that the ABLE Exoskeleton is feasible to be used by persons with SCI to perform skills for home and community environments.

The secondary hypothesis is that the device will have a positive impact on the perceived rate of exertion, mobility and psychosocial health, and quality of life and general health of the study participants with SCI.

This is a multicenter pre-post quasi-experimental study. The pre-post period will cover 22 exoskeleton sessions (18 training sessions and 4 assessment sessions) over a period of up to 8 weeks. The study will have two centres specialized in SCI involved, one at Heidelberg University, Germany and another at Institut Guttmann, Spain. In total 10 patients will be recruited.

After obtaining a Patient Information Sheet and Informed Consent Form (PIS/ICF), patients will be screened. Patients who match inclusion and exclusion criteria and pass pre-study screening, will be enrolled into the study. First, there will be a familiarisation session (session 0), where participants will learn how to use the device. Participants will then undergo a training programme with the ABLE Exoskeleton three to five times a week for up to 8 weeks for a total of 18 training sessions and 4 assessment sessions. The assessment sessions with the device will be performed at 4 time-points throughout training: Baseline (Session 1), Mid-training (Session 11), Final-training (Session 21) and Home-Skills-Test (Session 22). This therefore means there will be a total of 22 exoskeleton sessions, including training and assessments. During each training session, feasibility measurements will be taken via the evaluation of the performance of exoskeleton skills. Four weeks after the post-training assessment, a follow-up assessment will be conducted with participants. At the end of the study, the participating therapists will be asked to fill out a satisfaction questionnaire.

Being tested
ABLE Exoskeleton
Keywords
Spinal Cord Injury, Exoskeleton, Robotics, Gait Rehabilitation, Lower-limb, Neurorehabilitation, Paraplegia, Walking, Assistive technology, Usability, Feasibility, Home use, Community use, Multicenter
Medical subject headings
Spinal Cord Injuries, Paraplegia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ABLE ExoskeletonDevice

    The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.

Study groups in NCT05643313
Study groupRoleWhat they receive
TreatmentExperimentalParticipants will then undergo a training programme with the ABLE Exoskeleton three to five times a week for up to 8 weeks for a total of 18 training sessions and 4 assessment sessions.
Receives: Device: ABLE Exoskeleton

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time and Level of Assistance (LoA) to don/doff the device [Usability/Feasibility]

    Level of Assistance (LoA) and time taken to don/doff the device will be measured in every session. LoA will be measured using a 6-item scale, from Total assistance to Independence. Different assistance levels are defined taking into account the degree of participation of the patient and the therapist in performing the activity.

    Measured: Up to 11 weeks

  2. LoA to complete skills for home and community environments [Usability/Feasibility]

    The participant will attempt a set of skills for home and community environments every session to assess the device's usability. The therapist will record the LoA required to complete each task during every session. The best LoA-Score of all 15 tasks within 3 consecutive training sessions will be recorded and analysed (sessions 2-4, sessions 5-7, sessions 8-10, sessions 11-14, sessions 15-17, sessions 18-20).

    Measured: Up to 11 weeks

  3. Tme to complete Home-Skills-Test and LoA for each task and ti [Usability/Feasibility]

    A Home-skills-test will be performed by all participants and will consist of 10 of the skills for home and community environments, set out in a sequence to simulate daily life situations. The test will be attempted twice with a 5 min break in between, the best result will be documented. To assure safety, participants will attempt the test with assistance from the therapist as required.

    For all skills of the Home-skills-test, the LoA to complete each task and the time to complete the test will be documented.

    Measured: Up to 11 weeks

  4. Number of steps taken with the device [Usability/Feasibility]

    The ABLE Exoskeleton device will record the number of steps, walking time, standing time, and walking distance every session. This information will allow insight into the proportion of time spent training per session.

    Measured: Up to 11 weeks

  5. Distance walked with the device [Usability/Feasibility]

    The ABLE Exoskeleton device will record the number of steps, walking time, standing time, and walking distance every session. This information will allow insight into the proportion of time spent training per session.

    Measured: Up to 11 weeks

  6. Walking time with the device [Usability/Feasibility]

    The ABLE Exoskeleton device will record the number of steps, walking time, standing time, and walking distance every session. This information will allow insight into the proportion of time spent training per session.

    Measured: Up to 11 weeks

  7. Standing time in the device [Usability/Feasibility]

    The ABLE Exoskeleton device will record the number of steps, walking time, standing time, and walking distance every session. This information will allow insight into the proportion of time spent training per session.

    Measured: Up to 11 weeks

Secondary outcomes (10)

  1. BORG Scale [Perceived rate of exertion]

    Measurement of the perceived rate of exertion. The BORG will be tested after the 6 MWT with and without the device. The BORG scale measures the subjective level of intensity in physical work on a 15-grade scale. It ranges from 6 (No exertion at all) to 20 (Maximal exertion).

    Measured: Up to 11 weeks

  2. 6-Minute Walk Test (6 MWT) [Gait and function]

    The 6 Minute Walk Test (6 MWT) measures the distance a person can walk within six minutes. Several conditions are reported to perform the test. For this study we will use a 50 meter track, where the patients are walking back and forth.

    Measured: Up to 11 weeks

  3. 10-Meter Walking Test (10 MWT) [Gait and function]

    The 10 Meter Walk Test (10 MWT) measures the time a person needs to walk 10 meters. The test is performed with a dynamic (flying) start with two-meter acceleration, a timed ten-meter distance and a two-meter deceleration.

    Measured: Up to 11 weeks

  4. Timed up and go test (TUG) [Gait and function]

    Timed Up and Go Test (TUG) measures the time it takes a person to get up from a chair, walk 3 meters, turn around and sit down again. It is a widely used test to assess balance and the risk of falls in different patient groups.

    Measured: Up to 11 weeks

  5. Walking Index for Spinal Cord Injury (WISCI II) [Gait and function]

    The Walking Index for Spinal Cord Injury (WISCI II) assesses the extent and nature of assistance for walking 10 meters in persons with SCI. Assistance is specified as different combinations of braces, walking aids and physical assistance. The WISCI II consists of 20 levels from inability to walk to the ability to walk 10 meters without any assistance

    Measured: Up to 11 weeks

  6. Spinal Cord Independence Measure (SCIM III) [Gait and function]

    The Spinal Cord Independence Measure (SCIM) III scale focuses on the ability to perform activities of daily living in persons with SCI. The SCIM III consists of three subscales: Self-Care, Respiratory and Sphincter Management, Mobility (room and toilet) and Mobility (indoors and outdoors, on even surface). A total score of 0 (totally dependent) to 100 (totally independent) points can be achieved

    Measured: Up to 11 weeks

  7. Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) [User satisfaction]

    Used to measure user satisfaction from participants and therapists. The Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) is designed to measure the level of satisfaction and the value people attribute to assistive technologies. It does so using 12 variables which are scored on a 5 point scale in terms of perceived importance and satisfaction. While items 1-8 rate the satisfaction with the device, items 9-12 are for assessing the satisfaction with the service. If the users are not very satisfied with a feature, they are asked to provide specific feedback. The final score is the mean sum scores of all valid responses with a range of 1 (not satisfied at all) to 5 (very satisfied).

    Measured: Up to 11 weeks

  8. Psychosocial Impact of Assistive Devices Scales (PIADS) [Psychosocial impact on participants]

    The Psychosocial Impact of Assistive Devices Scales (PIADS) is a 26-item (7-point Likert-Scale), self-report questionnaire designed to assess the effects of an assistive device on functional independence, well-being, and quality of life. It is divided into three subscales: Competence, adaptability and self-esteem. For each of the subscales, typically means are calculated that range from -3 (maximum negative impact) to +3 (maximum positive impact). To have only positive sum scores, the range of the individual scores are shifted to 1 to 7, meaning that sum scores range from 1 *26 (26, maximum negative impact) to 7 *26 (182, maximum positive impact). The PIADS is a responsive measure and sensitive to important variables such as the user's clinical condition, device stigma, and functional features of the device. It has been shown to accurately reflect the self-described experiences of people who use assistive devices

    Measured: Up to 11 weeks

  9. WHO Quality of Life brief form (WHOQOL-BREF) [Participants Quality of Life assessment]

    The WHO Quality of Life-BREF (WHOQOL-BREF) is the short version of the WHOQOL-100 and is recommended for use when time is restricted or in use in clinical trials. It is a self-report questionnaire that contains 26 items and addresses 4 QOL domains: physical health, psychological health, social relationships and environment. Items are rated on a 5-point Likert scale (low score of 1, high score of 5) to determine a raw item score. Subsequently, the main score for each domain is calculated, resulting in a mean score per domain that is between 4 and 20. Finally, this mean domain score is then multiplied by 4 in order to transform the domain score into a scaled score, with a higher score indicating a higher QOL. When transformed by multiplying by 4, each domain score is then comparable to the scores in the original WHOQOL-100. Self-administration is recommended if the respondent has sufficient ability.

    Measured: Up to 11 weeks

  10. Self-report questionnaire on the perceived impact on general health.

    Participants' perceptions of the impact on their general health will be evaluated by the completion of a self-report questionnaire on the perceived impact on general health. This questionnaire has been designed by the researchers and intends to identify to what extent participants feel that the ABLE Exoskeleton is ready for home-use.

    Measured: Up to 11 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Dec 2022
  2. Study start25 Nov 2022
  3. Primary completion28 Aug 2023
  4. Study completion28 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05643313
Sponsor's protocol ID
ABLEexoSCI Home
Status last verified
Oct 2023
First submitted
25 Nov 2022
Last updated
19 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Nadorf F, Wright MA, Lopez-Matas H, Porras E, Carnicero-Carmona A, Hensel C, Franz S, Weidner N, Vidal J, Opisso E, Rupp R. User-centered design of a personal-use exoskeleton: a clinical investigation on the feasibility and usability of the ABLE Exoskeleton device for individuals with spinal cord injury to perform skills for home and community environments. Front Neurosci. 2024 Sep 26;18:1437358. doi: 10.3389/fnins.2024.1437358. eCollection 2024.

    PubMed 39391753

Questions about this trial

What is this clinical trial studying?

A study testing ABLE Exoskeleton in people with Spinal Cord Injuries, run by ABLE Human Motion S.L. at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time and Level of Assistance (LoA) to don/doff the device [Usability/Feasibility] (time frame: Up to 11 weeks). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05643313, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in